Project Grant R21AI194592
Award Date 8/14/26
Completion Date 7/31/28
Dollars Obligated $231K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Lexington, KY 40506, USA
Similar Awards
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $847,000 in Project Grant funding to The University of Kentucky Research Foundation on July 15, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research, scheduled for completion by June 30, 2027, focuses on identifying the protective roles of CD180 and nucleotide oligomerization domain 1 (NOD1)—two pathogen-associated molecular pattern...
- The National Institute of Allergy and Infectious Diseases awarded The University of Kentucky Research Foundation $420,063 on February 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and functionally characterize bacterial and phage proteins that control BB-1 bacteriophage production in Lyme disease spirochetes. The funded research targets the molecular switches governing the transition of BB-1 bacteriophages from dormant plasmid replication to lytic...
- The National Institute of Allergy and Infectious Diseases awarded $264,750 to the University of Washington on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of three transcriptional regulators—DR1, DRAP1, and BTAF1—in suppressing interferon responses triggered by self-RNA ligands. The research characterizes how loss of these proteins induces robust interferon responses and explores the immunostimulatory double-stranded RNA...
- The National Institute of Allergy and Infectious Diseases awarded Western University of Health Sciences $200,600 on August 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate noncanonical DNA virus sensing through an IKK-alpha-driven interferon signaling cascade. The research project maps a previously unrecognized antiviral signaling pathway that bypasses the canonical cGAS-STING-TBK1-IRF3 axis and instead utilizes IKK-alpha to drive type I interferon...
- The National Institute of Allergy and Infectious Diseases awarded The University of Kentucky Research Foundation $144,825 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support predoctoral trainee stipends and related costs for a transdisciplinary training program in microbiology and immunology. The program supports three predoctoral trainees per year, selected from PhD candidates in their third or fourth year of study across 18 faculty mentors at...
- The National Institute of Allergy and Infectious Diseases awarded the University of South Florida $791,245 on May 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate placental antiviral defense mechanisms. The funded research, organized around two specific aims, will elucidate how human trophoblasts produce type III interferons and defend against viral threats at the maternal-fetal interface. Aim 1 will define the mechanisms by which...
- The National Institute of Allergy and Infectious Diseases awarded $234,151 to the University of California, Davis on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the mechanism of mRNA polyadenylation in immunoglobulin heavy chain genes during the differentiation of activated B cells into plasma cells. The research leverages single-cell-level RNA measurement coupled with RNA hybridization-based flow cytometry and CRISPR-based genome...
- The National Institute of Allergy and Infectious Diseases awarded Beckman Research Institute of the City of Hope $489,500 on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and characterize novel molecular pathways regulating inflammatory responses, with particular focus on non-canonical mir-146a biogenesis and its role in immune homeostasis. The research will characterize post-transcriptional mechanisms controlling mir-146a production,...
- The National Institute of Allergy and Infectious Diseases awarded The University of Kentucky Research Foundation $184,592 on May 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate microbial contamination, persistence, and exposure pathways in flood-affected building materials. The research combines field-based floodwater sampling with controlled mesocosm experiments to track microbial colonization and persistence on common building materials...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $651,476 on August 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on the RNA helicase DDX39B and its regulation of alternative RNA splicing. The project grant, numbered R01AI192666, runs through July 31, 2030, with performance at the University of Virginia's Charlottesville, Virginia campus. The research investigates DDX39B's dual role in immune...